Combined liver and kidney transplantation

Enrico Benedetti, Jacques Pirenne, Christoph Troppmann, Nadey Hakim, Chul Moon, Rainer W. Gruessner, Harvey Sharp, Arthur J. Matas, William D. Payne, John S. Najarian

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Patients with end-stage renal and hepatic failure may be treated with combined liver and kidney transplantation (CLKTx). We reviewed the indications and outcomes of 16 CLKTx performed at the University of Minnesota between 1980 and 1994. The majority of the recipients (87.5%) were young patients affected by congenital hepatic anomalies and concomitant end-stage renal failure. Fourteen were treated with cyclosporin-based immunosuppression and had an excellent outcome: with an average of 6 years of follow-up, patient survival was 85.7%, liver graft survival 85.7%, and kidney graft survival 72%. The incidence of rejection episodes was similar to the rate of rejection in our solitary kidney and liver transplants. In conclusion, our experience supports the value of CLKTx in treating patients with simultaneous failure of both organs or with congenital enzymatic hepatic deficits leading to renal failure.

Original languageEnglish (US)
Pages (from-to)486-491
Number of pages6
JournalTransplant International
Volume9
Issue number5
StatePublished - 1996
Externally publishedYes

Fingerprint

Liver Transplantation
Kidney Transplantation
Liver
Graft Survival
Chronic Kidney Failure
Kidney
Liver Failure
Immunosuppression
Cyclosporine
Renal Insufficiency
Transplants
Survival
Incidence

Keywords

  • Kidney, liver transplantation
  • Liver, kidney transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Benedetti, E., Pirenne, J., Troppmann, C., Hakim, N., Moon, C., Gruessner, R. W., ... Najarian, J. S. (1996). Combined liver and kidney transplantation. Transplant International, 9(5), 486-491.

Combined liver and kidney transplantation. / Benedetti, Enrico; Pirenne, Jacques; Troppmann, Christoph; Hakim, Nadey; Moon, Chul; Gruessner, Rainer W.; Sharp, Harvey; Matas, Arthur J.; Payne, William D.; Najarian, John S.

In: Transplant International, Vol. 9, No. 5, 1996, p. 486-491.

Research output: Contribution to journalArticle

Benedetti, E, Pirenne, J, Troppmann, C, Hakim, N, Moon, C, Gruessner, RW, Sharp, H, Matas, AJ, Payne, WD & Najarian, JS 1996, 'Combined liver and kidney transplantation', Transplant International, vol. 9, no. 5, pp. 486-491.
Benedetti E, Pirenne J, Troppmann C, Hakim N, Moon C, Gruessner RW et al. Combined liver and kidney transplantation. Transplant International. 1996;9(5):486-491.
Benedetti, Enrico ; Pirenne, Jacques ; Troppmann, Christoph ; Hakim, Nadey ; Moon, Chul ; Gruessner, Rainer W. ; Sharp, Harvey ; Matas, Arthur J. ; Payne, William D. ; Najarian, John S. / Combined liver and kidney transplantation. In: Transplant International. 1996 ; Vol. 9, No. 5. pp. 486-491.
@article{84c8f18e18f141639af356b548eaecf3,
title = "Combined liver and kidney transplantation",
abstract = "Patients with end-stage renal and hepatic failure may be treated with combined liver and kidney transplantation (CLKTx). We reviewed the indications and outcomes of 16 CLKTx performed at the University of Minnesota between 1980 and 1994. The majority of the recipients (87.5{\%}) were young patients affected by congenital hepatic anomalies and concomitant end-stage renal failure. Fourteen were treated with cyclosporin-based immunosuppression and had an excellent outcome: with an average of 6 years of follow-up, patient survival was 85.7{\%}, liver graft survival 85.7{\%}, and kidney graft survival 72{\%}. The incidence of rejection episodes was similar to the rate of rejection in our solitary kidney and liver transplants. In conclusion, our experience supports the value of CLKTx in treating patients with simultaneous failure of both organs or with congenital enzymatic hepatic deficits leading to renal failure.",
keywords = "Kidney, liver transplantation, Liver, kidney transplantation",
author = "Enrico Benedetti and Jacques Pirenne and Christoph Troppmann and Nadey Hakim and Chul Moon and Gruessner, {Rainer W.} and Harvey Sharp and Matas, {Arthur J.} and Payne, {William D.} and Najarian, {John S.}",
year = "1996",
language = "English (US)",
volume = "9",
pages = "486--491",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Combined liver and kidney transplantation

AU - Benedetti, Enrico

AU - Pirenne, Jacques

AU - Troppmann, Christoph

AU - Hakim, Nadey

AU - Moon, Chul

AU - Gruessner, Rainer W.

AU - Sharp, Harvey

AU - Matas, Arthur J.

AU - Payne, William D.

AU - Najarian, John S.

PY - 1996

Y1 - 1996

N2 - Patients with end-stage renal and hepatic failure may be treated with combined liver and kidney transplantation (CLKTx). We reviewed the indications and outcomes of 16 CLKTx performed at the University of Minnesota between 1980 and 1994. The majority of the recipients (87.5%) were young patients affected by congenital hepatic anomalies and concomitant end-stage renal failure. Fourteen were treated with cyclosporin-based immunosuppression and had an excellent outcome: with an average of 6 years of follow-up, patient survival was 85.7%, liver graft survival 85.7%, and kidney graft survival 72%. The incidence of rejection episodes was similar to the rate of rejection in our solitary kidney and liver transplants. In conclusion, our experience supports the value of CLKTx in treating patients with simultaneous failure of both organs or with congenital enzymatic hepatic deficits leading to renal failure.

AB - Patients with end-stage renal and hepatic failure may be treated with combined liver and kidney transplantation (CLKTx). We reviewed the indications and outcomes of 16 CLKTx performed at the University of Minnesota between 1980 and 1994. The majority of the recipients (87.5%) were young patients affected by congenital hepatic anomalies and concomitant end-stage renal failure. Fourteen were treated with cyclosporin-based immunosuppression and had an excellent outcome: with an average of 6 years of follow-up, patient survival was 85.7%, liver graft survival 85.7%, and kidney graft survival 72%. The incidence of rejection episodes was similar to the rate of rejection in our solitary kidney and liver transplants. In conclusion, our experience supports the value of CLKTx in treating patients with simultaneous failure of both organs or with congenital enzymatic hepatic deficits leading to renal failure.

KW - Kidney, liver transplantation

KW - Liver, kidney transplantation

UR - http://www.scopus.com/inward/record.url?scp=9444284440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9444284440&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 486

EP - 491

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 5

ER -